Clinical Trial Update: Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation [Phase 1, Phase 2]

View source ↗

Summary

Teva-sponsored Phase 1/2 study completed evaluating the clinical equivalence of Mometasone Nasal Spray 50 mcg/actuation for seasonal allergic rhinitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• mometasone nasal spray (mometasone)

Snippet

Sponsor: Teva Pharmaceuticals USA | Conditions: Seasonal Allergic Rhinitis | Phase 1, Phase 2 | Status: COMPLETED